SNHG1 and hepatocellular carcinoma: Additionally, chemosensitivity analyses have demonstrated that lower expression of SNHG1 renders HCC cells more sensitive to several systemic agents, like AKT inhibitor VII, bexarotene, bicalutamide, dasatinib, erlotinib, and gefitinib, while higher expression of SNHG1 can lead to drug resistance [57].